HomeCompareNLRCF vs JNJ

NLRCF vs JNJ: Dividend Comparison 2026

NLRCF yields 3280.84% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NLRCF wins by $1068669155842.10M in total portfolio value
10 years
NLRCF
NLRCF
● Live price
3280.84%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1068669155842.13M
Annual income
$1,008,217,661,564,564,500.00
Full NLRCF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NLRCF vs JNJ

📍 NLRCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNLRCFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NLRCF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NLRCF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NLRCF
Annual income on $10K today (after 15% tax)
$278,871.39/yr
After 10yr DRIP, annual income (after tax)
$856,985,012,329,879,800.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, NLRCF beats the other by $856,985,012,329,875,800.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NLRCF + JNJ for your $10,000?

NLRCF: 50%JNJ: 50%
100% JNJ50/50100% NLRCF
Portfolio after 10yr
$534334577921.08M
Annual income
$504,108,830,782,284,600.00/yr
Blended yield
94.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NLRCF
No analyst data
Altman Z
-15.1
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NLRCF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNLRCFJNJ
Forward yield3280.84%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1068669155842.13M$30.3K
Annual income after 10y$1,008,217,661,564,564,500.00$4,689.40
Total dividends collected$1064508726528.01M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NLRCF vs JNJ ($10,000, DRIP)

YearNLRCF PortfolioNLRCF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$338,784$328,083.99$10,592$272.30+$328.2KNLRCF
2$10,750,312$10,387,813.35$11,289$357.73+$10.74MNLRCF
3$319,565,138$308,062,304.26$12,123$472.89+$319.55MNLRCF
4$8,900,344,933$8,558,410,234.49$13,141$629.86+$8900.33MNLRCF
5$232,293,399,740$222,770,030,662.02$14,408$846.81+$232293.39MNLRCF
6$5,682,346,050,574$5,433,792,112,852.62$16,021$1,151.60+$5682346.03MNLRCF
7$130,305,408,956,352$124,225,298,682,237.23$18,122$1,588.22+$130305408.94MNLRCF
8$2,801,751,583,965,647$2,662,324,796,382,350.50$20,930$2,228.20+$2801751583.94MNLRCF
9$56,496,723,623,895,864$53,498,849,429,052,620.00$24,792$3,191.91+$56496723623.87MNLRCF
10$1,068,669,155,842,133,100$1,008,217,661,564,564,500.00$30,274$4,689.40+$1068669155842.10MNLRCF

NLRCF vs JNJ: Complete Analysis 2026

NLRCFStock

Northern Lights Resources Corp. engages in the acquisition, evaluation, and exploration of mineral resource properties in the United States. The company explores for gold, silver, zinc, and lead deposits. It holds a 100% interest in the Medicine Springs project consists of 149 unpatented federal mineral claims covering an area of approximately 1,189 hectares located in southeastern Elko County, Nevada; and the Secret Pass Gold project, which includes 84 unpatented lode mining claims covering an area of approximately 868 hectares located in northwestern Arizona. The company was formerly known as Northern Lights Uranium Corp. and changed its name to Northern Lights Resources Corp. in April 2008. Northern Lights Resources Corp. was incorporated in 2007 and is headquartered in Vancouver, Canada.

Full NLRCF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NLRCF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NLRCF vs SCHDNLRCF vs JEPINLRCF vs ONLRCF vs KONLRCF vs MAINNLRCF vs ABBVNLRCF vs MRKNLRCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.